Special Considerations in the Management of HIV-Infected Patients From Minority Communities
Summary
- GS-236-0102 and GS-236-0103 trials compared coformulated cobicistat/elvitegravir/emtricitabine/tenofovir DF with efavirenz/emtricitabine/tenofovir DF and atazanavir/ritonavir in treatment-naive patients receiving emtricitabine/tenofovir DF[Sax 2012; DeJesus 2012]
- Efficacy of the elvitegravir-based regimen did not differ by race at Week 96[Cooper 2013]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content